$MNKKQ News
Last published 3d ago
- 3d agoMNKKQKeenova Therapeutics plc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 4y agoMNKKQMallinckrodt Emerges from Chapter 11 with Strengthened Balance Sheet and Enhanced Financial FlexibilityPR NewswireAppoints Sigurdur Olafsson as President and Chief Executive Officer DUBLIN, Ireland, June 16, 2022 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company") today announced that it has successfully completed its reorganization process, emerged
- 4y agoMNKKQMallinckrodt Provides a Regulatory Update on TerlipressinPR NewswireDUBLIN, Feb. 22, 2022 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Company's New Drug Applica
- 4y agoMNKKQMallinckrodt Plan of Reorganization Confirmed by U.S. CourtPR NewswireDUBLIN, Feb. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKKQ) ("Mallinckrodt" or the "Company") today announced that its Plan of Reorganization (the "Plan") has been confirmed by the U.S. Bankruptcy Court for the District of Delaware, paving the way
- 4y agoMNKKQMallinckrodt Earns Top Marks Again in Human Rights Campaign Foundation's 2022 Corporate Equality IndexPR NewswireDUBLIN, Jan. 31, 2022 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKKQ), a global biopharmaceutical company, announced that it received a score of 100 on the Human Rights Campaign Foundation's 2022 Corporate Equality Index, the U.S.'s foremost benchmarking
- 4y agoMNKKQMallinckrodt Announces Enrollment of First Patient in Phase 1/2a StrataSOMA Clinical Trial of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for Investigating the Treatment of Full-Thickness BurnsPR NewswireDUBLIN, Dec. 16, 2021 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKKQ), a global biopharmaceutical company, today announced enrollment of the first patient in StrataSOMA, a Phase 1/2a clinical trial that is assessing StrataGraft® (allogeneic cultured kera
- 4y agoMNKKQNew Data on Patients with Cutaneous T-cell Lymphoma Treated with Extracorporeal Photopheresis from a Retrospective Study Presented at the American Society of Hematology Annual MeetingPR NewswireDUBLIN, Dec. 13, 2021 /PRNewswire/ -- Mallinckrodt plc, (OTC:MNKKQ) a global biopharmaceutical company, today announced results of a retrospective, observational medical chart review study assessing real world treatment outcomes among cutaneous T-cell l
- 5y agoMNKKQBuxton Helmsley Publicly Responds to Departure of Mallinckrodt Plc. CCO, After Open Letter to U.S. SEC Detailing Accounting FraudBusiness WireThe Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, "BHG" or "we"), the New York City-based investment advisor to clients with significant holdings of Mallinckrodt Plc. ("Mallinckrodt" or the "Company") (OTC:MNKKQ) comm
- 5y agoMNKKQMallinckrodt Presents Results from Two Retrospective Studies on Real World Characteristics and Outcomes of Patients with Hepatorenal Syndrome Type-1 (HRS-1) at The Liver Meeting Digital ExperiencePR NewswireDUBLIN, Nov. 12, 2021 /PRNewswire/ -- Mallinckrodt plc, (OTC:MNKKQ) a global biopharmaceutical company, today announced findings from two retrospective medical chart review studies on real world outcomes of patients hospitalized with hepatorenal syndrome
- 5y agoMNKKQBRKSU.S. CREDIT WEEK AHEAD: Lower Yields May Spur Heavy BorrowingBloomberg
- 5y agoMNKKQBuxton Helmsley Publicly Responds to Resignation of Mallinckrodt Plc. SVP, Finance, Days After Open Letter to U.S. SEC Detailing Accounting FraudBusiness WireThe Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, "BHG" or "we"), the New York City-based investment advisor to clients with significant holdings of Mallinckrodt Plc. ("Mallinckrodt" or the "Company") (OTC:MNKKQ) comm
- 5y agoMNKKQThe Buxton Helmsley Group Calls on U.S. Securities and Exchange Commission to Intervene in Mallinckrodt Plc. Fraud Involving False Statements of Financials, Insider Trading on Undisclosed Information, and Electoral TamperingBusiness WireThe Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, "BHG" or "we"), the New York City-based investment advisor to clients with significant holdings of Mallinckrodt Plc. ("Mallinckrodt" or the "Company") (OTC:MNKKQ) comm
- 5y agoMNKKQMallinckrodt Presents Results on Real World Treatment Patterns and Outcomes in Hospitalized Patients with Esophageal Variceal Hemorrhage and Liver Cirrhosis Treated with Terlipressin at the American College of Gastroenterology Annual Scientific MeetingPR NewswireDUBLIN, Oct. 25, 2021 /PRNewswire/ -- Mallinckrodt plc, (OTC:MNKKQ) a global biopharmaceutical company, today announced results from a retrospective medical chart review study examining treatment patterns and outcomes in hospitalized patients with esoph
- 5y agoMNKKQMallinckrodt Reaches Settlements with the Official Committee of Opioid Related Creditors, the Official Committee of Unsecured Creditors and Second Lien NoteholdersPR NewswireDUBLIN, Sept. 3, 2021 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached an agreement with the Official Committee of Opioid Related Creditors (the "OCC") and the Restructuring Support Agree
- 5y agoMNKKQMallinckrodt Announces Publication of Phase 3 STRATA2016 Study in BurnsPR NewswireDUBLIN, July 7, 2021 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKKQ), a global biopharmaceutical company, today announced publication of results from the pivotal Phase 3 STRATA2016 clinical trial of StrataGraft® (allogeneic cultured keratinocytes and der
- 5y agoMNKKQMallinckrodt Announces Inclusion of Acthar® Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) Treatment Guidelines for Patients with Pulmonary SarcoidosisPR NewswireDUBLIN, July 1, 2021 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKKQ), a global biopharmaceutical company, today announced new treatment guidelines for sarcoidosis from the European Respiratory Society (ERS), which include use of Acthar® Gel (repository co
- 5y agoMNKKQMallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat)PR NewswireDUBLIN, June 15, 2021 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblast
- 5y agoMNKKQCCLU.S. CREDIT WEEK AHEAD: Corporate Debt Holds Up Amid VolatilityBloomberg
- 5y agoMNKKQMallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Keratitis at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingPR NewswireDUBLIN, May 3, 2021 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKKQ), a global biopharmaceutical company, today announced data from its Phase 4, multi-center, open-label study to assess the efficacy and safety of Acthar® Gel (repository corticotropin injec
- 5y agoMNKKQMallinckrodt Presents Data Evaluating INOmax® (Nitric Oxide) Gas, for Inhalation in a Phase 4 Observational Registry in Neonates with Pulmonary Hypertension at the Pediatric Academic Societies (PAS) 2021 Virtual MeetingPR NewswireDUBLIN, April 30, 2021 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKKQ), a global biopharmaceutical company, today announced that data from its Phase 4 observational registry comparing the safety and effectiveness of INOmax® (nitric oxide) gas, for inhalati
- 5y agoMNKKQMallinckrodt Moves Ahead With Plan to Hand Company to CreditorsBloomberg
- 5y agoJPMMCOMNKKQENDPEndo Aims to Rework $3.3 Billion Loan as Opioid Litigation LoomsBloombergEndo International Plc is trying to get more breathing room on its debt as it contests with ongoing opioid and patent litigation and an expected drop in earnings.
- 5y agoMNKKQDeutsche Bank Struggles to Shift Debt for German Opioid-MakerBloombergDeutsche Bank AG is struggling to offload hundreds of millions of euros of debt for German pharmaceutical company Gruenenthal GmbH due to a lack of interest from investors, according to people familiar with the matter.
- 6y agoMNKKQEscalating Debt Brawls Add to Headache for Distressed CompaniesBloombergAs the pace of large U.S. company bankruptcies stabilizes, escalating tensions between distressed companies, private equity owners and creditors signal more bruising Chapter 11 filings to come.
- 11y agoMNKKQENDPValeant Drop Ripples Through Drug StocksBloombergA $20 billion selloff in Valeant Pharmaceuticals International Inc. spurred a battering in drug stocks seen as sharing its taste for acquisitions, sending Mallinckrodt Plc and Endo International Plc tumbling.
- 12y agoMNKKQMallinckrodt to Buy Questcor in $5.6 Billion Drugs DealBloombergMallinckrodt Plc agreed to buy Questcor Pharmaceuticals Inc. for $5.6 billion to add specialty drugs in the latest industry deal that moves a U.S. company to Ireland for a lower tax rate.
- 12y agoMNKKQMallinckrodt to Buy Pain-Drug Maker Cadence for $1.3 BillionBloombergMallinckrodt Plc, the drugmaker spun off by Covidien Plc last year, agreed to buy Cadence Pharmaceuticals Inc. for about $1.3 billion in cash to add a pain treatment used in hospitals.